Completed PHASE2 INTERVENTIONAL 1-arm NCT00509379

Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma (LYM-2023)

A Phase II Multicenter Non-randomized Study to Assess Safety, Toxicity and Clinical Activity of the Association of Bortezomib(VELCADE)With Rituximab in Relapsed/Refractory Indolent Non Follicular and Mantle-cell Non-Hodgkin Lymphoma

Sponsor: Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Conditions Lymphoma Non-Hodgkin Lymphoma

Interventions Rituximab VELCADE

Updated 7 times since 2017 Last updated: Jan 27, 2011 Started: Sep 30, 2006 Primary completion: Nov 30, 2007 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lymphoma and Non-Hodgkin Lymphoma and is currently completed. Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jun 2023 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Fondazione Italiana Linfomi - ETS
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
University of Turin, Italy

Data source: Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Bari, Italy , Bologna, Italy , Brescia, Italy , Cagliari, Italy , Candiolo, Italy , Chivasso, Italy , Cirié, Italy , Cuneo, Italy , Florence, Italy and 11 more locations